TVTX
Travere Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$52.42
+6.09%Next report
Analyst consensus
- Next report date
- Feb 18, 2027
- EPS estimate
- $0.39
- Revenue estimate
- $244.9M
Latest reported
- Last report date
- Nov 2, 2026
- EPS actual
- -$0.55
- EPS estimate
- -$0.06
- Revenue actual
- $224.6M
- Revenue estimate
- $195.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -274.2%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $74
- PT range
- $67 – $78
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 2, 2026 | -$0.06 | -$0.55 | Miss -891.88% | $224.6M |
| Aug 4, 2026 | -$0.13 | -$0.37 | Miss -174.79% | $169.6M |
| May 4, 2026 | -$0.30 | -$0.39 | Miss -30.00% | $127.2M |
| Feb 19, 2026 | $0.03 | $0.03 | In line | $129.7M |
| Oct 30, 2025 | -$0.31 | $0.28 | Beat 190.32% | $164.9M |
| May 1, 2025 | -$0.55 | -$0.47 | Beat 14.55% | $81.7M |
| Feb 20, 2025 | -$0.58 | -$0.73 | Miss -25.86% | $74.8M |
| Oct 31, 2024 | -$0.70 | -$0.70 | In line | $62.9M |
| Aug 1, 2024 | -$0.87 | -$0.90 | Miss -3.45% | $54.1M |
| Feb 15, 2024 | -$1.27 | -$1.16 | Beat 8.66% | $45.1M |
| Aug 3, 2023 | -$1.16 | -$1.13 | Beat 2.59% | $59.7M |
| May 4, 2023 | -$1.18 | -$1.27 | Miss -7.63% | $57.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 18, 2027